4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Beijing Tsingke Biotech Co., Ltd., a pioneer in molecular manufacturing, showcased its next-generation integrated platforms ...

Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on ...

For decades, synthetic biologists have been developing gene circuits that can be transferred into cells for applications such as reprogramming a stem cell into a neuron or generating a protein that ...

REGENXBIO completes pivotal enrollment and initiates commercial production in Duchenne gene therapy programme: Rockville, Maryland Friday, October 31, 2025, 18:00 Hrs [IST] REGENX ...

GeneVentiv Therapeutics, Inc., a privately held biotechnology company developing one-time gene therapies for rare and inherited diseases, today announced that it held a successful INTERACT meeting ...

Foghorn is advancing a Selective EP300 degrader program, with an initial focus in MM and DLBCL, on track for IND-enabling studies in 2026. Key updates include: VHL based selective degrader shows ...

Overview of Epigenetics MarketThe global Epigenetics Market is valued at USD 2.56 Billion in 2024 and is projected to reach a value of USD 9.11 Billion by 2035 at a CAGR (Compound Annual Growth Rate) ...

New scientific article warns of loss of consumer trust unless proper analysis is done. Report: Claire Robinson ...

Tenaya Therapeutics, Inc. (($TNYA)) announced an update on their ongoing clinical study. Tenaya Therapeutics, Inc. is conducting a pivotal ...